MiraDx Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 19

Employees

  • Latest Deal Type
  • 2ndary - Private

MiraDx General Information

Description

Developer of pharmacogenomics tests for radiation therapy designed to improve the assessment of individual cancer risk. The company's pharmacogenomics tests personalize cancer treatment and provide women with information about the risk of ovarian and breast cancer that they face, enabling hospitals to prevent and cure cancer in women.

Contact Information

Website
www.miradx.com
Formerly Known As
3PrimiR
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 11600 Wilshire Boulevard
  • Suite 2410
  • Los Angeles, CA 90025
  • United States
+1 (424)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 11600 Wilshire Boulevard
  • Suite 2410
  • Los Angeles, CA 90025
  • United States
+1 (424)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MiraDx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private 01-Apr-2021 Completed Generating Revenue
2. Early Stage VC (Series A) 23-Aug-2010 Completed Generating Revenue
1. Early Stage VC 01-Jan-2009 Completed Generating Revenue
To view MiraDx’s complete valuation and funding history, request access »

MiraDx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view MiraDx’s complete cap table history, request access »

MiraDx Patents

MiraDx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4103277-A1 Biomarkers for predicting toxicity of radiation Pending 12-Feb-2020
EP-4103277-A4 Biomarkers for predicting toxicity of radiation Pending 12-Feb-2020
US-20230103419-A1 Biomarkers for predicting toxicity of radiation Pending 12-Feb-2020
WO-2021163609-A1 Biomarkers for predicting toxicity of radiation Inactive 12-Feb-2020
AU-2018283314-A1 Biomarkers for predicting tumor response to and toxicity of immunotherapy Active 15-Jun-2017 C12Q1/6886
To view MiraDx’s complete patent history, request access »

MiraDx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MiraDx FAQs

  • When was MiraDx founded?

    MiraDx was founded in 2008.

  • Where is MiraDx headquartered?

    MiraDx is headquartered in Los Angeles, CA.

  • What is the size of MiraDx?

    MiraDx has 19 total employees.

  • What industry is MiraDx in?

    MiraDx’s primary industry is Biotechnology.

  • Is MiraDx a private or public company?

    MiraDx is a Private company.

  • What is MiraDx’s current revenue?

    The current revenue for MiraDx is .

  • How much funding has MiraDx raised over time?

    MiraDx has raised $4.16M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process